Cargando…
Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
BACKGROUND: Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis...
Autores principales: | Chan, Marcia A, Gigliotti, Nicole M, Dotson, Abby L, Rosenwasser, Lanny J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875359/ https://www.ncbi.nlm.nih.gov/pubmed/24004581 http://dx.doi.org/10.1186/2045-7022-3-29 |
Ejemplares similares
-
Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab
por: Kulka, M, et al.
Publicado: (2010) -
Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020) -
IgG and IgE Autoantibodies to IgE Receptors in Chronic Spontaneous Urticaria and Their Role in the Response to Omalizumab
por: Maronese, Carlo Alberto, et al.
Publicado: (2023) -
Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE
por: R, Divya, et al.
Publicado: (2020) -
Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)